序号1行政处罚决定书文号渝药监妆处罚〔2025〕2号案件名称重庆市新立华康日用化工厂未经许可生产销售未备案化妆品案违法企业名称或违法自然人名称重庆市新立华康日用化工厂违法企业组织机构代码证/ 统一社会信用代码9150010562200783X4        法定代表人/负责人姓名周密主要违法事实当事人未经许可生产销售未备案的化妆品。当事人的行为违反了《化妆品监督管理条例》第十七条和第二十七条的规定。行政处罚内容依据《化妆品监督管理条例》第五十九条第一款第一项的规定，责令当事人改正违法行为，并决定给予行政处罚如下：1.没收违法所得7604元；2.没收违法生产经营的化妆品和专门用于违法生产经营的原料、包装材料等物品；3.罚款8万元。决定机关名称重庆市药品监督管理局处罚决定日期2025.09.04公示日期2025.09.08备注

行政相对人名称鹤岗市普爱医药销售有限公司宝泉岭分公司行政相对人代码(统一社会信用代码)91230400MA1CDKPW6A法定代表人徐丽艳行政处罚决定书文号萝市监处罚〔2025〕42号违法行为类型从非法渠道购进药品、未按规定凭处方销售处方药及未按规定开具销售凭证违法事实从非法渠道购进药品、未按规定凭处方销售处方药及未按规定开具销售凭证处罚依据《中华人民共和国药品管理法》处罚类别罚款处罚内容1、警告；2没收违法所得485元；3、罚款5000元。罚款金额（万元）0.5没收违法所得没收非法财物的金额（万元）0.0485处罚决定日期2025-09-08处罚有效期2025-09-08公示截止期2028-09-08处罚机关萝北县市场监督管理局

Delivery Method:Via EmailProduct:DrugsRecipient:Seann GlossPureRawz1404 Lakeshire Dr.Knoxville,TN37922United Statessupport@purerawz.coIssuing Office:Center for Drug Evaluation and Research (CDER)United StatesWARNING LETTERSeptember 8, 2025RE: 715218Dear Seann Gloss:This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://purerawz.co in August 2025 and has observed that your website offers products for sale in the United States (U.S.), including the following: “Tianeptine Ethyl Ester Sulfate,” “Tianeptine Free-Acid,” “Tianeptine Sodium,” “Tianeptine Sulfate,” and “Tianeptine Ultimate” (hereinafter your Tianeptine products). We have also reviewed your social media accounts at www.facebook.com/purerawz/ and www.instagram.com/purerawzrevolution/. Your social media accounts direct consumers to your https://purerawz.co website to purchase your products. Based on our review, your Tianeptine products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d), as described below.Furthermore, FDA has warned consumers about products containing tianeptine, which is used as a prescription drug in some European, Asian, and Latin American countries but is not an FDA-approved drug in the U.S. The FDA is aware of several serious adverse event reports associated with tianeptine and that consumers may find themselves addicted to tianeptine.1Despite statements on your product labeling marketing your products “for laboratory and research use only,” evidence obtained from your websites establish that your products are intended to be drugs for human use. Based on our review of your labeling, your Tianeptine products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended to prevent, treat, mitigate, or cure disease conditions and/or affect the structure or any function of the body. Examples from your product labeling, including on your website and social media accounts that provide evidence of the intended use (as defined in 21 CFR 201.128) of your products as drugs for human use include, but may not be limited to, the following:On your webpages https://purerawz.co/product/tianeptine-ethyl-ester-sulfate/ and https://purerawz.co/product/tianeptine-free-acid/:“Tianeptine is a compound used primarily in research as a method to treat major depressive disorder[].”On your webpages https://purerawz.co/product/tianeptine-ethyl-ester-sulfate/ and https://purerawz.co/product/tianeptine-ultimate/:“Tianeptine is also currently being investigated for its efficacy in treating depression in Parkinson’s disease and in post-traumatic stress disorder, as well as asthma and irritable bowel syndrome.”On your “Tianeptine Sodium” webpage https://purerawz.co/product/tianeptine-sodium/:“Tianeptine Sodium is a unique tricyclic compound known for its antidepressant and anxiolytic properties. Tianeptine sodium exhibits a distinct mechanism of action, making it an excellent option for patients with depressive disorders, particularly those who have not responded to conventional treatments.”“Tianeptine Sodium is used to treat major depressive disorder (MDD), anxiety disorders, and sometimes for the management of irritable bowel syndrome (IBS). It is also explored for its neuroprotective and cognitive-enhancing effects.”“Potential Benefits[:] Potentially Effective in Treating Depression[,] Reduces Anxiety Symptoms[,] Enhances Cognitive Function[,] Neuroprotective Properties[, and] Minimal Sexual Dysfunction.”On your “Tianeptine Ultimate” webpage https://purerawz.co/product/tianeptine-ultimate/:“As an antidepressant tianeptine is similar to amitriptyline, imipramine, and fluoxetine, tianeptine exhibits efficacy against major depressive episodes, but with much fewer adverse effects.”“Asthma patients and respiratory depression have shown great success with tianeptine.”“In addition to its analgesic and anticonvulsant properties, tianeptine also has anticonvulsant properties.”“The effectiveness of tianeptine in the treatment of attention-deficit hyperactivity disorder has been demonstrated, and its adverse effects are kept to a minimum.”On your “Tianeptine Restrictions” webpage https://purerawz.co/tianeptine-restrictions/:“Tianeptine is a unique yet controversial compound that has garnered the intention of researchers worldwide. Initially developed in the 1980s as a treatment for depression, Tianeptine is currently classified as an atypical tricyclic antidepressant. Research shows it works by modifying the glutamatergic system by controlling AMPA and NMDA receptors. This unique mode of action allows Tianeptine to improve serotonin reuptake in specific brain areas. This is in contrast to conventional antidepressants that raise serotonin levels.”On your Instagram and Facebook social media accounts at www.instagram.com/purerawzrevolution/ and www.facebook.com/purerawz/:March 12, 2025 post: “Break the chaos. Find clarity . . . Unleash the untapped potential of Tianeptine Sodium—a powerhouse for emotional balance, razor-sharp mental clarity, and relentless stress relief.”Additionally, your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the treatment of disease and/or to affect the structure or function of the body. Examples of such testimonials include, but are not limited to, the following:“I suffer from depression and this has helped me so much to feel more positive and optimistic.” [From the Reviews section of the “Tianeptine Ethyl Ester Sulfate” product webpage https://purerawz.co/product/tianeptine-ethyl-ester-sulfate/]“This helped stabilize my mood and allow my overall mental health instantaneously.” [From the Reviews section of the “Tianeptine Free-Acid” product webpage https://purerawz.co/product/tianeptine-free-acid/]“My anxiety has taken a back seat, and I’m feeling more motivated and focused than ever.” [From the Reviews section of the “Tianeptine Sodium” product webpage https://purerawz.co/product/tianeptine-sodium/]“I love this product[.] I have intrusive thoughts and sensations of fear that cause anxiety/panic. I take 2 of these and within 15 mins my body sensations disappear and my mind is quiet.” [From the Reviews section of the “Tianeptine Sulfate” product webpage https://purerawz.co/product/tianeptine-sulfate/]“I have used this Tianeptine Ultimate for many months due to depression and anxiety. This product does help a lot and takes the edge off enough to calm me.” [From the Reviews section of the “Tianeptine Ultimate” product webpage https://purerawz.co/product/tianeptine-ultimate/]Moreover, your Tianeptine products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the above-described conditions prescribed, recommended, or suggested in their labeling. Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).ConclusionThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “715218” in the subject line of the email.Sincerely,/S/Tina Smith, M.S.Captain, U.S. Public Health ServiceDirectorOffice of Unapproved Drugs and Labeling ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration_____________________1See https://www.fda.gov/consumers/consumer-updates/tianeptine-products-linked-serious-harm-overdoses-death.

序号行政处罚决定书文号案件名称违法企业名称或违法企业自然人姓名违法企业组织机构代码法定代表人姓名主要违法事实行政处罚的种类和依据作出处罚的机关名称和日期备注1黔药监行罚〔2025〕33号安顺市宝林科技中药饮片有限公司生产劣药蔓荆子案安顺市宝林科技中药饮片有限公司统一社会信用代码：915204903221896356于以祥生产劣药处罚种类：1.没收非法财物；2.没收违法所得；3.罚款。                            处罚依据：《中华人民共和国药品管理法》第一百一十七条第一款。贵州省药品监督管理局      2025年9月2日2黔药监行罚〔2025〕34号贵阳宇顺气体有限公司未遵守药品生产质量管理规范案贵阳宇顺气体有限公司统一社会信用代码：915201002144505846李性良未遵守药品生产质量管理规范处罚种类：罚款。                            处罚依据：《中华人民共和国药品管理法》第一百二十六条。贵州省药品监督管理局      2025年9月3日

根据《中华人民共和国行政许可法》《医疗器械生产监督管理办法》等有关规定，经中航迈特增材制造（固安）有限公司申请，我局决定依法注销其《医疗器械生产许可证》。特此公告。附件：《医疗器械生产许可证》注销名单河北省药品监督管理局2025年9月8日序号企业名称许可证编号社会信用 代码法定 代表人企业 负责人生产地址和生产 范围注销原因1中航迈特增材制造（固安）有限公司冀药监械生产许20230007号91131022MA07P52736高正江张飞（2002年分类）：（2017年分类）：Ⅲ类:17-06口腔义齿制作材料企业申请

安徽省药监局医疗器械生产监督检查信息通告（2025年8月）序号监督检查企业名称企业类别检查方式检查结论组织单位检查时间1以诺康医疗科技（合肥）有限公司三类日常检查基本符合省局第一分局2025-08-012安徽方达药械股份有限公司三类飞行检查不符合药品审评查验中心2025-08-013滁州釉美生物技术有限公司二类日常检查基本符合省局第五分局2025-08-044安徽科奇医疗器械有限公司二类日常检查不符合省局第一分局2025-08-055安徽宸晟医疗器械有限公司二类日常检查基本符合省局第四分局2025-08-056安徽清大德人医疗科技股份有限公司二类飞行检查/长期停产省局第五分局2025-08-057合肥赫博医疗器械有限责任公司二类日常检查基本符合省局第一分局2025-08-068宽腾（安徽）医疗科学技术有限公司三类日常检查基本符合省局第五分局2025-08-069安徽媄健达医疗科技有限公司二类日常检查基本符合省局第五分局2025-08-0610合肥天一生物技术研究所有限责任公司三类日常检查基本符合省局第一分局2025-08-0711安徽乐轩义齿有限公司二类日常检查基本符合省局第二分局2025-08-0812安徽泾县裕生医疗器械有限公司二类日常检查不符合省局第八分局2025-08-0813合肥天达诊断试剂有限公司二类日常检查基本符合省局第一分局2025-08-1214合肥永康电子科技有限公司二类日常检查不符合省局第一分局2025-08-1415安徽法罗适医疗技术有限公司二类日常检查基本符合省局第九分局2025-08-1416安徽国泰国瑞医疗科技有限公司二类飞行检查不符合药品审评查验中心2025-08-1517安徽易硕医学科技有限公司二类飞行检查基本符合省局第九分局2025-08-1518安徽汇诚医疗科技有限公司三类日常检查基本符合药品审评查验中心2025-08-1619尼普洛医疗器械（合肥）有限公司三类飞行检查基本符合药品审评查验中心2025-08-1620安徽京环医疗用品有限公司三类飞行检查基本符合药品审评查验中心2025-08-1621安徽维视达康光学技术有限公司三类日常检查基本符合药品审评查验中心2025-08-1622安徽迈力医疗科技有限公司三类飞行检查基本符合药品审评查验中心2025-08-1623安徽安盛医疗科技有限公司三类飞行检查基本符合药品审评查验中心2025-08-1624安徽奥弗医疗设备科技股份有限公司二类飞行检查基本符合药品审评查验中心2025-08-1625合肥百盛园生物药业有限公司二类飞行检查不符合药品审评查验中心2025-08-1726砀山县八方义齿有限公司二类日常检查基本符合省局第四分局2025-08-1827多特医学器材制造（合肥）有限公司二类日常检查基本符合省局第一分局2025-08-1928合肥和尔适科技发展有限公司二类日常检查基本符合省局第一分局2025-08-2029黄山市屯溪区天利和义齿制作中心二类日常检查基本符合省局第八分局2025-08-2030安徽以心医疗器械有限公司二类日常检查基本符合省局第四分局2025-08-2131安徽呈瑞医疗设备有限公司二类有因检查符合省局2025-08-2132上海华源安徽仁济制药有限公司二类日常检查基本符合省局第三分局2025-08-2133宿州迈动数康科技有限公司二类日常检查基本符合省局第四分局2025-08-2234安徽宜美健医疗用品有限公司二类日常检查基本符合省局第五分局2025-08-2235安徽省小山卫生材料有限公司二类日常检查基本符合省局第八分局2025-08-2236安徽泰阳医疗技术服务有限责任公司二类日常检查基本符合省局第一分局2025-08-2637安徽研实科技有限公司二类日常检查基本符合省局第一分局2025-08-2738安徽康源药械有限公司二类日常检查基本符合省局第三分局2025-08-28

按照《行政许可法》(中华人民共和国主席令第7号)第七十条及《医疗器械生产监督管理办法》（国家市场监督管理总局令第53号）第二十一条的相关规定，现就注销成都斯马特科技股份有限公司《医疗器械生产许可证》有关事宜公告如下：因成都斯马特科技股份有限公司申请终止医疗器械生产，现拟依法注销该公司《医疗器械生产许可证》。该公司持有的《医疗器械生产许可证》内容为：企业名称为成都斯马特科技股份有限公司；住所为成都高新区合作路 333 号 1 栋 1 层 1 号、2 栋 1 层 1 号；生产地址为成都高新区合作路 333 号 1 栋 1 层 1 号 306-316、2 栋 1 层 1 号四楼南区；法定代表人为冉鹏；企业负责人为冉鹏；生产范围 2002 年分类目录：Ⅱ类：6840-2-生化分析系统 2017 年分类目录：Ⅱ类：22-02-生化分析设备,22-03-电解质及血气分析设备,22-04-免疫分析设备 。自本公告发布之日起10个工作日内，如无单位、个人提出异议，本机关将依法注销该公司《医疗器械生产许可证》。 特此公告。联系电话：028-86913062                       四川省药品监督管理局                              2024年9月5日

依据《中华人民共和国行政许可法》第七十条、《执业药师注册管理办法》第二十四条的规定，现将《执业药师注册证》注销情况予以公告。　　附件：注销的注册证内容                                　　　　　　　　　　　　　　　　　　　　　　　　　 重庆市药品监督管理局                                   　　　　　　　　　　　　　　　　　　　　　　　　 2025年9月4日附件注销的注册证内容 序号姓名性别执业单位《执业药师注册证》编号1李吉明男重庆市梁平区明辉大药房5012202802382毛世义女重庆市梁平区魏英药品经营部5012202802733陶勇男重庆市梁平区益寿堂大药房5012202802274黄园园男重庆市梁平区佳康彭学儿药店5012252800755袁锦丽女重庆市梁平区五加六康梁大药房5012222800216余波女重庆市梁平区万和大药房有限公司屏锦店5012242801217陈丽鹂女重庆修竹大药房连锁有限公司一分公司5022238502538兰桂雪女重庆修竹大药房连锁有限公司二分公司5022238502319钟世波男重庆修竹大药房连锁有限公司三分公司50222385023210黄云翔男重庆市万和药房连锁有限公司万盛区万盛大道三店50222510003011夏德丽女重庆市全兴药品连锁有限公司万盛二分店50122585008712郑立柱男重庆必强塔山大药房（个人独资）50122010037113赵艳女重庆必强大药房（个人独资）50122410047314夏万芳女重庆市万盛经开区济上药房50222410044715李欢欢女重庆良方医药有限公司500222410018916赵刚男重庆市渝北区古路赋康药店50122512001917周庆雪女渝北张帮卫大药房50122412053918黎琴琴女重庆市渝北区源华大药房50122012072119钱宇女重庆市渝北区麦克红康民惠药房50122412115320胡丁文女重庆市渝北区惠芝佳药店50222312018021胡琮英女重庆春之天药房50122112020422何智科男重庆桐亨阁大药房有限公司50122512046423陈旭女重庆市渝北区华烨康年诚益药房50222412053324周波女重庆市渝北区百姓花园路药房（个人独资）50222412119125黄邦美女重庆市渝北区誉康老药房有限公司50122412100226李强男麦克红康药房渝北区黎均药店50222412117627肖富丽女重庆市渝北区敖奇全大药房50122112069228李丽女重庆德康阁昌婷药房有限公司50122312001229吴兴萍女药医森园港路（重庆）医药有限公司50222512008730刘宗游女药医森堡桐路（重庆）医药有限公司50122412055931王华女重庆德康阁元祥大药房50122412081932侯文礼女重庆市聚药阁祥源药品有限公司50122312048433汪炜男重庆市渝北区桐君阁空港乐园马毅大药房店50122112090334赵飞男重庆港湾泰斛堂药房50122112063135胡娟女重庆市鑫海源一百五十八药房50122512042936谭家智男重庆鼎新荟鑫彦渝汇药房有限公司50222412083437尹小琴女重庆华忠语彤药房有限公司50122212006738赖雅洁女重庆市渝北区华忠均益药房50122212067639任娟女重庆市渝北区桐君阁歧黄药房50122512006440杨朝轩男重庆千方阁大药房连锁有限公司渝北区志宁药店50222012084241周颖女重庆市真善美上善大药房有限公司50222512038642陶毅男渝中区半岛万和药房有限公司较场口店50122403010843邓雪女重庆良心医药有限公司荣昌区棠悦路分公司50122453021044谢峰男渝中区半岛万和药房有限公司菜袁路店50122403010945周建鸿男忠县健之生药店（个人独资）50222433025046刘秋林男忠县惠豪药店（个人独资）50222533016347王丹丽女忠县桂英药房（个人独资）50222533000648张小瑜女忠县汝晋药店（个人独资）501224330241

“安全”二字，以细微之处的安心与幸福，深植人心。2020至2024年内蒙古药品质量抽查检验合格率逐年上升，由2020年的97.5%上升至2024年的99.73%，2022至2025年上半年内蒙古药品质量抽查检验合格率更是始终稳定在99%以上；全区近五年未发生药品安全事件；五年来共查办600余件药品犯罪案件……一串串跃动的数字，记录着内蒙古药品监管系统五年来奋进的足音。“十四五”规划收官之年，自治区药监局呈上一份来之不易、含金量高的安全成绩单——这五年，自治区药监局深入贯彻落实党和国家关于药品监管改革的决策部署，聚焦自治区“贯穿一条主线，办好两件大事，弘扬蒙古马精神，闯新路进中游”，持续完善全区药品安全治理体系，内蒙古药品安全形势稳定向好。讲政治 药品安全使命在肩习近平总书记对药品安全工作高度重视、高度关切，深刻指出药品安全责任重于泰山，保障药品安全是技术问题、管理工作，也是道德问题、民心工程。保障药品安全是药品监管部门最基本的职责，药品安全是民生大事，更是不可撼动的政治责任。内蒙古自治区党委、政府高位推动建设药品安全责任体系，坚决扛起疫苗药品安全政治责任，出台党委和政府领导班子及其成员药品安全责任制规定、药品安全工作评议考核办法、疫苗药品安全突发事件应急预案……将药品安全责任深度融入地方政府考核评价体系，深入开展督查指导，推动落实属地管理和监管部门责任，构建起层层传导、环环相扣的责任闭环。防风险 问题苗头及时化解每个季度，全区药监系统各层级都会组织风险会商，收集风险点，研究防控措施。“我们把工作立足点放在不出事上，深挖细查可能存在的风险隐患，抓早、抓小、抓苗头，采取有效措施及时化解。”自治区药监局药品安全监察处处长王晓丽信心满满。突出药品、化妆品、医疗器械全生命周期质量安全监管，内蒙古建立自治区、盟市、旗县三级药品安全风险会商制度，通过梳理排查药、化、械各环节风险点，建立详实台账并实施动态销号管理，风险管控由被动应对转向主动治理。分片组织召开实地观摩、交流座谈、集体约谈，分类组织开展承诺践诺，定期邀请区内外专家学者解读药品监管政策、分享管理经验，督促引导“两品一械”生产经营使用单位切实履行质量安全主体责任。组织41名处级干部包联70家高风险和重点监管企业，指导企业发现并解决质量安全管理体系等问题115个……一系列举措，只为让监管始终跑在风险的前面。严监管 整治行动硬核出击各级药品监管部门紧盯疫苗、特殊药品、无菌和植入类医疗器械、儿童及特殊化妆品等重点品种，网络销售、医疗机构药品使用等重点环节，农村牧区、城乡接合部等重点区域，新建企业等重点对象，综合运用日常巡查、专项检查、交叉互查、抽检监测、投诉举报等手段加强监管，使风险识别更精准，防控措施更到位，为药品安全保驾护航。与此同时，药品安全专项行动压茬开展，各类检查方式协同发力，监督抽检与风险监测双轨并行，形成强大的风险过滤网，消除了一批风险隐患，维护了药品市场秩序：药品安全专项整治行动扎实开展，联合公安部门公开征集11类“两品一械”违法犯罪线索，开辟涉案产品检验绿色通道，以最快速度出具认定意见；药品安全巩固提升行动见行见效，坚持源头治理，督促企业落实质量安全主体责任，连续部署开展医疗机构制剂备案后监督检查，集采中选药械产品、医疗美容用械、化妆品“一号多用”等多项专项检查；药品经营环节“清源”行动深入推进，聚焦药品购进渠道、票据管理、运输仓储等关键环节，通过飞行检查、明察暗访等手段，严打非法渠道购进、虚构流向、伪造票据等违法行为。强震慑 案件查办提升质效“我从网上看到了今年1月6日药品监管执法人员检查时发现一家药店因售卖超过有效期药品被查处的新闻，大快人心，确实能感受到近几年药店经营越来越规范了，我们老百姓用药也能更加安心。”赤峰市民卓女士露出欣慰的笑容。群众关心的，就是我们要尽心的。自治区药监局印发《检查与稽查衔接管理办法》，完善规范检查与稽查衔接程序：建立联动机制，加强检查与稽查部门之间的协作，检查中对于可能存在重大违法行为或明显涉嫌违法的情况，可通知稽查部门提前介入，双方共同调查取证，形成监管合力；明确严谨的移交处置程序，对于属于自治区药监局直接管辖或盟市、旗县市场监管局管辖的案件，检查组及时报告并填写移交单，连同证据材料一并移交给相应的稽查部门，提高了案件查办的时效性。对集采中选品种、医疗美容药械、定制式义齿及化妆品“一号多用”等群众反映强烈的问题实施重拳惩治，并通过跨层级督导12315线索核查，严查国家药监局明确的20项重点违法行为，坚决杜绝以调代罚、有案不立，对严重违法违规企业有关负责人实施联合惩戒、行业禁入、从业禁止……这些硬核举措对药品安全违法违规行为形成强大震慑，彰显出内蒙古自治区严厉打击药品违法违规行为的坚定态度。这五年，内蒙古持续强化药品不良反应监测，不断提升不良反应监测能力，依法监督上市许可持有人落实药物警戒责任。医疗器械不良事件“一键化”报告实现各盟市全覆盖，为药品安全筑起坚实的“防火墙”。习近平总书记强调，要切实加强食品药品安全监管，用最严谨的标准、最严格的监管、最严厉的处罚、最严肃的问责，加快建立科学完善的食品药品安全治理体系，坚持产管并重，严把从农田到餐桌、从实验室到医院的每一道防线。药监把关，使命必达。沿着习近平总书记指引的方向，我们信念如磐、步伐坚定、矢志前行。这份安全答卷背后，是守护每一个生命健康的坚定承诺，更是牢牢守住药品安全底线、助力建设健康中国的坚强决心。

根据《广东省食品药品监督管理局关于〈药品经营许可证〉注销的管理规定》（粤食药监法〔2013〕26号），至2025年9月5日，我局已依法注销连平县乡亲大药房有限公司等药店的《药品经营许可证》。现予以公布。许可证号许可证标明的有效期限企业名称法人代表/负责人注销日期注销原因粤DA76205522028年6月11日连平县乡亲大药房有限公司何海芹2025年9月5日企业申请河源市连平县市场监督管理局2025年9月5日